logo
JEC Hosts 5th International Ophthalmology Summit, Launches Groundbreaking Digital Eye Health Platform

JEC Hosts 5th International Ophthalmology Summit, Launches Groundbreaking Digital Eye Health Platform

Korea Herald22-05-2025

JAKARTA, Indonesia, May 22, 2025 /PRNewswire/ -- JEC Eye Hospitals and Clinics, Indonesia's leading eye care provider with more than four decades of clinical excellence, hosts the fifth edition of JEC International Meeting (JECIM) 2025 and launches the nation's first AI-powered digital eye health encyclopedia, Matapedia.
The return of JECIM, after its last edition in 2020, marks a significant moment for global eye care collaboration. Under the theme "Shaping the Future of Vision," the three-day scientific forum features pioneering discussions on AI-assisted retinal diagnostics, semi-robotic surgical tools, hospital management for practitioners managing hospitals and eye clinics to meet global standards, a 3D surgery experience— the first of its kind in Indonesia —which allows participants to feel as if they are directly involved in an eye surgery through special glasses, and innovative approaches to combat vision impairment in high-prevalence regions. The forum attracts over 1,200 eye care professionals from 17 countries for groundbreaking discussions on cutting-edge diagnostic tools, surgical innovations, and global strategies to improve vision care. The participants include ophthalmologists—among them young ophthalmologists and members of the ophthalmology community—eye care nurses, optometrists/refractionists-opticians, and other eye health industry practitioners.
DR. Dr. Johan Hutauruk, Sp.M(K), CEO of JEC Corporation said, "At JEC, our mission is rooted in the belief that a clear vision is fundamental to a better quality of life. Every step we take is driven by a commitment to help people see better—because when people see better, they live better. That belief drives everything we do—especially through platforms like the JEC International Meeting, which we are proud to host as part of our commitment to elevating eye care in Indonesia and beyond. JECIM is more than just a medical symposium—it is a vital convergence of knowledge, innovation, and collaboration. We bring together world-class ophthalmologists, researchers, and professionals to exchange ideas, share the latest breakthroughs, and empower one another."
JEC International Meeting (JECIM) 2025 is the most comprehensive ophthalmology scientific forum in Indonesia, initiated by JEC and held every two years. JECIM has become the most comprehensive ophthalmology scientific forum in Indonesia— reinforcing JEC's ongoing contribution to advancing eye health not only domestically but also internationally.
Founded in 1984, JEC's legacy as Indonesia's most advanced and comprehensive eye hospital network is well-established, both nationally and internationally. In terms of reach, JEC now operates five state-of-the-art eye hospitals: JEC @ Menteng, JEC @ Kedoya, JEC PRIMASANA @Tj. Priok, JEC CANDI @Semarang, and JEC ORBITA @Makassar. It also runs eleven leading eye clinics in major Indonesian cities, including JEC @ Cibubur, JEC @ Tambora, JEC @ Cinere, JEC @ Bekasi, Candi Eye Center @ Semarang, JEC ANWARI @Purwokerto, JEC JAVA @Surabaya, JEC ORBITA @Makassar, JEC BALI @Denpasar, JEC JAVA @Pasuruan, and the newly opened JEC ORBITA @Kendari. Later this year, JEC will add a few other branches to bring access to trusted, international-standard eye care services closer to not only for local communities, but also for international visitors and even residents of neighboring countries.
Its flagship facility, JEC @ Kedoya, has earned four consecutive accreditations from the Joint Commission International (JCI)—in 2014, 2017, 2020, and 2023—cementing its status as a global-standard institution in patient safety and clinical excellence. This achievement serves as a benchmark for the standardization of JEC's services across all its branches.
A pioneer in vision correction, JEC made history by being the first hospital in Indonesia to introduce LASIK surgery and launch the country's first Laser Vision Correction Center (LVC). For this groundbreaking achievement, JEC was awarded a record by the Indonesian World Records Museum (MURI) for its contributions to LASIK services.
Domestically, JEC has achieved the highest level of accreditation from the Hospital Accreditation Commission (KARS) and received numerous accolades, including the title of Most Brand Reputable Eye Hospital in Greater Jakarta and seven other major cities across Indonesia by SWA Magazine, as well as Best in Building and Managing Corporate Image in the Eye Hospital category from the Corporate Image Award. In addition, JEC was recognized for its excellence in Omnichannel Branding in 2023 and as the winner of the Digital Customer Engagement category at the 2024 Marketeers OMNI Awards.
On the international stage, JEC is a founding member of the ASEAN Association of Eye Hospitals (AAEH) and an active member of the World Association of Eye Hospitals (WAEH), further reinforcing its role as a regional leader in ophthalmic care.
As the most complete eye care provider in Indonesia, JEC offers a full spectrum of advanced treatments, including cataract surgery (Phacoemulsification and FLACS), refractive procedures like SMILE PRO, SMILE, and LASIK, as well as specialized care for corneal diseases, vitreoretinal disorders, glaucoma, and neuro-ophthalmology. JEC also leads in oculoplasty (eye plastic surgery and ocular tumors), ocular infections and immunology, and provides services, namely general eye exams, tele-ophthalmology, dry eye care, contact lens services, and myopia control. For pediatric and specific cases, JEC offers specialized clinics including the Children's Eye & Strabismus Center, Low Vision Care, and the Thyroid Eye Center for thyroid-related vision conditions.
In a groundbreaking move at JECIM 2025, JEC unveiled Matapedia — a comprehensive and accessible digital platform dedicated to eye health. Matapedia serves as a trusted source of accurate, easy-to-understand information about eye conditions, treatments, and preventive care, aiming to empower the public and support medical professionals in enhancing vision and quality of life. All of this information can be accessed free of charge by the general public through the website www.matapedia.id.
Dr. Referano Agustiawan, SpM(K), Director of JEC @ Menteng and Chair of JECIM 2025, said the high-profile gathering has become the ideal stage to introduce this groundbreaking digital solution. "JECIM has always been about pushing boundaries in eye care. Matapedia, on the other hand, represents a vital bridge between cutting-edge ophthalmology and public accessibility. While JECIM advances professional knowledge sharing, this digital platform extends our expertise directly to communities facing critical eye care shortages."
Developed in response to Indonesia's severe ophthalmologist shortage - with just 3,000 specialists serving 275 million people - Matapedia combats an equally urgent crisis: medical misinformation. Findings from Indonesia's Communications and Digital Ministry (KOMDIGI), which identified 163 health misinformation cases among 1,923 hoaxes circulating in 2024 are concerning. Given that 27.79% of Indonesians look for health information online, Indonesia's 2024 Digital Literacy Index, however, shows a score of 43,34, indicating that while the public is fairly skilled in using digital devices, they tend to buy the information blindly.
The platform's "Ask AI" feature provides instant symptom guidance in multiple languages. JEC is also developing a mobile application with full accessibility features for the visually impaired, including screen readers and interactive audio guides. All content undergoes rigorous review by JEC's specialist network, presenting complex medical information through text, audio, and video formats.
DR. Dr. Johan Hutauruk, Sp.M(K), added, "Matapedia represents the culmination of our 41-year commitment to advancing eye care. This platform bridges our clinical expertise with digital innovation to address critical gaps in eye health education and literacy. From rural health workers to urban families, Matapedia delivers trustworthy knowledge exactly when and where it's needed."
Initial content covers hundreds of conditions and procedures, with plans to expand to 1,000+ articles by 2026. The forthcoming mobile app will incorporate screen reader technology and interactive audio guides, furthering JEC's commitment to inclusive care.
With a powerful combination of extensive clinical capacity, decades of experience, and the integration of cutting-edge digital technology, JEC continues to strengthen its position as a leader in eye care services in Southeast Asia. Through JECIM and Matapedia, JEC not only advances professional development in the medical field but also creates a meaningful social impact by expanding public access to accurate, high-quality eye health information.
About JEC
With 41 years of experience since its establishment in 1984, JEC's contribution to eye care services has been widely recognized through numerous prestigious awards and achievements. These include four consecutive accreditations from the Joint Commission International (JCI), awarded to JEC @ Kedoya in 2014, 2017, 2020, and 2023; recognition as the first LASIK pioneer in Indonesia, granted to "JEC LASIK Center" by MURI (Indonesian World Records Museum) in 2007; and Full Paripurna Accreditation from the Indonesian Ministry of Health. JEC has also received accolades such as "Indonesia Healthcare Most Reputable Brand" in 2014 and 2015 for the eye hospital category in Greater Jakarta and seven major cities in Indonesia from SWA Magazine, and "Best Corporate Image" from 2015 to 2019.
JEC is a pioneer in establishing the ASEAN Association of Eye Hospitals (AAEH) and remains an active member, alongside its involvement in the World Association of Eye Hospitals (WAEH).
To date, JEC operates five eye hospitals and eleven main eye clinics across major Indonesian cities, including JEC @ Menteng, JEC @ Kedoya, JEC PRIMASANA @Tj. Priok, JEC CANDI @ Semarang, and JEC ORBITA @ Makassar. The clinics include JEC @ Cibubur, JEC @ Tambora, JEC @ Cinere, JEC @ Bekasi, Candi Eye Center @ Semarang, JEC ANWARI @ Purwokerto, JEC JAVA @ Surabaya, JEC ORBITA @ Makassar, JEC BALI @ Denpasar, JEC JAVA @ Pasuruan, and JEC ORBITA @ Kendari.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

Korea Herald

time9 hours ago

  • Korea Herald

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact

Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market

Korea Herald

time18 hours ago

  • Korea Herald

Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market

KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®

Korea Herald

timea day ago

  • Korea Herald

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®

MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store